Induction of Apoptosis in Human Cancer Cells by Human Eb- or Rainbow Trout Ea4-Peptide of Pro-Insulin-Like Growth Factor-I (Pro-IGF-I) by Maria J. Chen et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Induction of Apoptosis in Human Cancer Cells 
by Human Eb- or Rainbow Trout Ea4-Peptide of 
Pro-Insulin-Like Growth Factor-I (Pro-IGF-I) 
Maria J. Chen, Chun-Mean Lin and Thomas T. Chen 
Department of Molecular and Cell Biology, University of Connecticut, Storrs, CT,  
USA  
1. Introduction 
Insulin-like growth factors (IGFs)-I and -II are members of the insulin family that play 
essential roles in regulating growth, development and metabolism in all vertebrates (de 
Pablo et al., 1990, 1993; Stewart and Rotwein, 1996). Like many peptide hormones, IGFs are 
initially produced as pre-pro-hormones containing an amino-terminal signal peptide, 
followed by the mature peptide of B, C, A, and D domains, and a carboxyl terminal E-
domain. Via post-translational processing, the signal peptide and the E-peptide are 
proteolytically cleaved off from the pre-pro-peptide, and both the mature IGFs and E-
peptides are secreted into the circulation (Rotwein et al., 1986; Duguay 1999). From 
molecular characterization of IGF-I gene and its transcription products, multiple isoforms of 
IGF-I mRNA were identified from fish to mammals. In human, three different species of 
IGF-I mRNAs which encode three isoforms of pro-IGF-I (i.e., pro-IGF-Ia, -Ib and Ic) were 
identified (Rotwein et al., 1986; Duguay 19995). These three isoforms of pro-IGF-I contain an 
identical mature IGF-I with 70 amino acid residues (aa) and different E-peptides with 30 aa 
(Ea), 77 aa (Eb) and 40 aa (Ec), respectively. The a-type E-domains are highly conserved 
among vertebrates but the b-type E-peptides are conserved in the first 15 amino acids and 
different thereafter among human, rats and mice (variable region).  
In fish, multiple isoforms of IGF-I transcripts have also been identified. These different 
isoforms of IGF-I transcripts encode an identical mature IGF-I but different E-peptides. 
Shamblott and Chen (1992, 1993) reported the presence of four different IGF-I transcripts 
encoding four different isoforms of pro-IGF-I for rainbow trout (Oncorhynchus mykiss). 
Similar to the isoforms of human pro-IGF-I, the four different isoforms of the rainbow trout 
pro-IGF-I contain an identical mature IGF-I (70 aa) and four different lengths of E-peptides 
(i.e., rtEa1, 35 aa; rtEa2, 47 aa; rtEa3, 62 aa; rtEa4, 74 aa). The first 15 amino acid residues of 
these four E-peptides are identical among themselves and the a-type E-peptides of 
mammals, and the 20 amino acid residues at the C-termini share 70% identity with their 
human counterparts. The rtEa1-peptide is composed of the first 15 and the last 20 amino 
acid residues. Insertion of either 12 or 27 amino acid residues between the first and the last 
segments of rtEa1-peptide results in rtEa2- or rtEa3-peptide, whereas insertion of both 
segments into rtEa1-peptide gives rise to rtEa4-peptide. Similar to rainbow trout, four 
different forms of Ea-peptides of pro-IGF-I have also been identified in Chinook salmon, 
www.intechopen.com
 Targeting New Pathways and Cell Death in Breast Cancer 
 
46
Coho salmon (Duguay et al., 1992: Willis and Devlin, 1993), and red drum (Faulk et al., 
2010). However, not all teloests possess four different E-peptides. While gilthead seabream 
possesses three different E-peptides (namely Ea1, Ea2 and Ea4), zebrafish and grouper each 
has only one Ea-peptide: Ea2-peptide in zebrafish and Ea4-peptide in grouper (Chen et al., 
2001; Shi et al., 2002; Tiago et al., 2008). 
Although the biological activity of the mature IGF-I has been extensively studied, the 
biological activity of E-peptides has been over-looked until recently. It was generally 
assumed that E-peptides of pro-IGF-I may be biologically inert; however the following lines 
of evidence suggest that E-peptides may possess biological activity. First, many peptide 
hormones are initially synthesized as complex pro-hormone molecules and following post-
translational processing to generate multiple peptides with distinct or similar biological 
activities. Examples are pro-opiomelanocortin (Civelli et al., 1986), pro-glucaogon (Bell et al., 
1983) and pro-insulin (Ido et al., 1997), just to name a few. In a similar manner, generation of 
E-peptides from pro-IGF-I may suggest a pluripotential role for these peptides. Second, the 
E-domains of pro-IGF-I are evolutionally conserved. Third, different isoforms of pro-IGF-I 
transcripts are expressed in a tissue-specific and developmental stage-specific manner, and 
exhibiting differential responses to growth hormone (Shamblott and Chen 1993; Duguay 
1994; Yang and Goldspink 2002). Siegfried et al. (1992) reported the first evidence that hEb-
peptide contained biological activity. In their studies, Siegfried and colleagues showed that 
a synthetic peptide amide with 23 amino acid residues (Y-23-R-NH2) of the hEb-peptide (a.a. 
103-124) at 2-20 nM exerted mitogenic activity in normal and malignant human bronchial 
epithelial cells. They further demonstrated that Y-23-R-NH2 bound to specific high affinity 
receptors (Kd = 2.8 ± 1.4 x 10-11M) present at 1-2 x 104 binding sites per cell and the ligand 
binding was not inhibited by recombinant insulin or IGF-I. Several investigators have 
reported recently that the Eb-peptide of rodent pro-IGF-I peptide (same sequence as hEc-
peptide) possessed activity in promoting proliferation of rodent myoblasts, whereas Ea-
peptide stimulated differentiation of mature myoblasts (Yang and Goldspink 2002; Matheny 
et al., 2010). Besides exerting mitogenic activity in rodent myoblasts by rodent Eb-peptide, 
murine Ea-peptide of pro-IGF-I also modulates the entry of mature IGF-I protein into 
C2C12, a murine skeletal muscle cell line (Pfeffer et al., 2009).  
Evidence documenting the biological activity of E-peptides of rainbow trout pro-IGF-I came 
from studies conducted by Tian et al. (1999). Tian et al. reported that recombinant rtEa2-, 
rtEa3- and rtEa4-peptides but not Ea1-peptide exhibited a dose dependent mitogenic 
activity in NIH 3T3 cells and carprine mammary gland epithelial cells (CMEC). Recently, 
Mark Chen in Taiwan also demonstrated that Ea2-peptide of zebrafish exerted a stimulatory 
effect on incorporation of 35S-sulfate into zebrafish gill bronchial cartilage in a sulfation 
assay (personal communication). These results are consistent with those reported in 
mammals (Siegfried et al., 1992; Matheny et al., 2010; Yang and Goldspink 2002). Further 
studies conducted in our laboratory showed that both recombinant rtEa4- or synthetic hEb-
peptide exerted unexpected anti-cancer cell activities in established human cancer cell lines 
such as MDA-MB-231, HT-29, HepG2, SK-N-F1, SKOV-3A, PC-3 and OVCAR-3B (Chen et 
al., 2002, 2007; Kuo and Chen 2002). These activities include: (i) induction of morphological 
differentiation and inhibition of anchorage-independent growth, (ii) inhibition of invasion 
and metastasis, and (iii) inhibition of cancer-induced angiogenesis.  
Programmed cell death, i.e., apoptosis, is a crucial process of eliminating unwanted cells in 
animal life, and it is vital for embryonic development, homeostasis and immune defense 
(Elmore 2007, for review). Apoptosis is characterized by typical morphological and 
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biochemical hallmarks, such as cell shrinkage, nuclear DNA fragmentation and plasma 
membrane blebbing (Hengartner, 2000). Results of extensive studies revealed that two 
pathways, extrinsic pathway (death receptor triggered pathway) and intrinsic pathway 
(mitochondrial pathway) can lead to apoptosis (Hengartner, 2000; Fulda and Debatin, 2006). 
Furthermore, there is ample evidence indicating that these two pathways are linked, and 
molecules from one pathway can influence the other pathway. One striking feature of cancer 
cells is that they do not readily undergo apoptosis due to reduction of expression or 
mutation of pro-apoptotic genes such as caspase genes (Ghavani et al., 2009) while 
increasing expression of anti-apoptotic genes such as Bcl-2 family genes (Youle and Strasser, 
2008). Certain anti-cancer drugs and agents which have been identified as potential effective 
cancer treatment can restore normal apoptotic pathways (Fulda and Debatin, 2006; Yang et 
al., 2008). Since rtEa4- and hEb-peptides have been shown to possess anti-cancer activities in 
vitro in a variety of human cancer cells (Kuo and Chen, 2002; Chen et al., 2007), it would be 
of great interest to determine if these peptides can also induce apoptosis in human cancer 
cells. In this paper, we report that rtEa4- and hEb-peptide of pro-IGF-I induces apoptosis in 
various human cancer cell lines via both extrinsic and intrinsic pathways. 
2. Materials and methods 
2.1 Cell culture 
Single-cell subclones were isolated from the aggressive breast cancer cells (MDA-MB-231), 
ovarian cancer cells (OVCAR and SKOV), neuroblastoma cells (SK-N-SH and SK-N-F1) and 
non-cancerous foreskin cells (CCD-1112SK) [all purchased from ATCC, Mannassas, VA] 
were routinely maintained in F12/DMEM (Gibco-BRL, Rockville, MD) supplemented with 
10% fetal bovine serum (FBS, Gibco-BRL) at 37oC under a humidified atmosphere of 5% 
CO2. Each cell line was sub-cultured every 3 days. 
2.2 Preparation of rtEa4- and hEb-peptides 
Recombinant rtEa4-peptide, hEb-peptide and control protein were prepared following the 
method described by our laboratory (Tian et al., 1999; Kuo and Chen, 2002; Chen et al., 
2007). Briefly, E. coli cells, transformed with an expressing vector pET-15b (Novagen, EMD 
Chemicals, Gibbstown, NJ) containing the coding sequence of rtEa4-peptide or hEb-peptide, 
were cultured in 5 ml of LB broth for 4 h, diluted to 500 ml LB broth and allow the culture to 
grow at 37 oC. The culture was induced with 1 mM isopropyl β-D-thiolactopyranoside 
(IPTG) at an OD600 of 0.6-0.8 for 2 h. Induced cells were harvested by low speed 
centrifugation and resuspended in 10 ml of a binding buffer (50 mM imidazole, 0.5 M NaCl, 
20 mM Tris-HCl, pH 7.9). Following ultrasonication, the cell lysate was obtained by 
centrifugation at 39,000g for 20 min. The recombinant protein, containing His-tags, was 
isolated by affinity chromatography on His-bind resin (Novagen) and followed by extensive 
dialysis in 1X PBS buffer to remove immidazole. The purity of the recovered recombinant 
protein was accessed to be about 80% by electrophoresis on SDS-polyaccrylamide gels. The 
control protein was prepared from E. coli cells harboring the backbone of the expression 
vector without E-peptide insert following the same method as described above.   
2.3 Microscopic observation of apoptotic cells induced by recombinant rtEa4-peptide 
Cancer cells (MDA-MB-231C and SKOV-3A) in serum free medium were treated with 
various concentrations (1.4 µM or 2.8 µM) of recombinant rtEa4-peptide or control protein 
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for 2 h, and were observed under an inverted phase contrast microscope (Olympus IX50) to 
determine apoptotic cells. SKOV-3A cells, after treated with 1.5 µM or control protein for 3 
days, were stained with H33258 and observed under an inverted phase contrast microscope 
(Olympus IX50).  
MDA-MB-231C cells in serum free medium were treated with rtEa4-peptide (3.0 µM) or 
same concentration of control protein for 48 h. One sample was treated with H202 for 16 h to 
induce apoptosis to serve as a positive control. TUNEL assay was carried out following the 
protocol supplied by the manufacturer (Roche Diagnostics Corp., Indianapolis, IN).  MDA-
MB-231C cells treated with rtEa4-peptide or control protein were stained with Rodamine 
Red labeled mono-specific polyclonal rabbit anti-activated capase 3 immunoglobulin 
(Biocompare, South San Francisco, CA) following conditions provided by the manufacturer. 
All images were observed under an inverted microscope (Olympus IX50) equipped with 
epifluorescence attachment. 
2.4 Quantitative relative real-time RT-PCR analysis 
Cancer cells (MDA-MB-231C, SKOV-3A, OVCAR-3B, SK-N-SH, and SK-N-F1) and non-
immortalized foreskin cells (CCD-1112SK) were treated with recombinant rtEa4-peptide (2.0 
µM), hEb-peptide (0.5 µM) or control protein for 6 h and RNA samples were prepared from 
these cells using Trizol reagent following the manufacturer’s protocol (Invitrogen, Carlsbad, 
CA). Each RNA sample was treated with RNase-free DNase to remove any DNA 
contamination during isolation. To confirm that the RNA samples were free of DNA 
contamination, RNA samples were used as templates for direct amplification of β-actin 
sequence without prior reverse transcription. One micrograsm of total RNA was reverse 
transcribed in a 20 µl reaction volume, containing 100 ng of oligo(dT)18, 10 nM dNTP, 
200mM DTT, 1 x reverse transcription buffer, and 1 µl SuperScripR III reverse transcriptase 
(Invitrogen) for 90 min at 42 oC, and the reverse transcription product was diluted to 100 µl 
with buffer. The PCR reaction was carried out in a 96-well plate with a final volume of 20 µl 
per well. The reaction mixture consists 1 X Sso fast EvaGreen Supermix (BioRad) containing 
Sso7d-fusion polymerase (BioRad), 500 nM of each forward and reverse primers (Table 1), 
and 4 µl of cDNA products. The amplification profile is as the following: 1 cycle of 95 oC for 
2 min, 40 cycles of 95 oC for 2 sec and 60 oC for 10 sec annealing and synthesis (conditions 
provided by BioRad). The cycle threshold, CT, was determined from the fluorescence value 
which was 10 times the mean standard deviation of fluorescence of the base line cycles, and 
the efficiency of amplification in all of the genes determined is 95-98%. The relative 
expression was determined using the arithmetic formula:  
2-[(SΔCT-CΔCT)], where SΔCT is the difference in CT values between the gene of interest in cells 
treated with rtEa4- or hEb-peptide and the house keeping gene (hGAPDH) in the sample, 
and CΔCT is the difference in CT values between the gene of interest in cells treated with 
control protein and the housekeeping gene (hGAPDH) of the control sample. Each 
experiment was repeated three times (n=3). 
3. Results and discussion 
Earlier studies conducted in our laboratory showed that recombinant rtEa4- or synthetic 
hEb-peptide of pro-IGF-I inhibited anchorage-independent growth and invasion of established 
human breast cancer cells (MDA-MB-231C), colon cancer cells (HT-29), ovarian cancer cells 
www.intechopen.com
 Induction of Apoptosis in Human Cancer Cells by E-Peptide of Pro-IGF-I 
 
49 
(OVCAR-3A and SKOV-3B), neuroblastoma cells (SK-N-F1), human hepatoma cells (HepG-2) 
and rainbow trout hepatoma cells (RTH) in vitro (Chen et al., 2002; Kuo and Chen 2002). Chen 
et al. (2007) also showed that seeding of aggressive human breast cancer cells (MDA-MB-231C) 
onto the chorioallantoic membrane (CAM) of five-day old chicken embryos resulted in rapid 
growth of MDA-MB-231C cells into cancer nodules, invasion of the cancer cells and induction 
of the blood vessel formation in and around the cancer mass. The growth, invasion and 
angiogenesis by MDA-MB-231C cells on the chicken CAM was inhibited by treatment with a 
single or multiple doses rtEa4 or hEb-peptide. By microarray and quantitative relative real-
time RT-PCR analyses, Chen et al. (2007) have further shown that a group of genes related to 
cancer cell activities were up- or down-regulated in MDA-MB-231C cells transfected with a 
cDNA encoding rtEa4-peptide. Together, these results suggest that rtEa4-or hEb-peptide may 
be developed as therapeutics for treating human cancers. 
 
 
Table 1. Gene specific primers used in comparative real-time RT-PCR analysis 
Cancer cells do not undergo apoptosis because they bypass apoptosis through a series of 
complex mechanisms involving dynamic interplays between cancer causing genes, 
oncogens, and/or mutated suppressor genes (Fulda and Debatin, 2004; Lowe and Lin, 2000). 
Apoptosis dysregulation in many cancers is one of the major hindrances towards the 
destruction of cancers in cancer therapy. Therefore, drugs and agents which can restore the 
normal apoptosis signaling pathways are considered as effective therapeutic agents for 
treating cancers (Evan and Vousden, 2001; Finkel 1999; Max 2002). Since rtEa4- or hEb-
peptide suppresses anchorage-independent growth, invasion and angiogenesis of many 
different cancer cells in vitro (Chen et al., 2002, 2007; Chen and Kuo, 2002), it would be of 
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great interest to know whether the protein can induce apoptosis in cancer cells. Treatment of 
ovarian cancer cells (SKOV-3A) or breast cancer cells (MDA-MB-231C) cells with 
recombinant rtEa4-peptide (1.4 and 2.8 µM) for 2 h, many cells exhibited distinct 
morphology of membrane blebbing, cell shrinkage, and chromatin condensation and 
disintegration (Fig 1). These morphological characteristics are consistent with those reported 
for apoptosis (Hacker 2000, for review).  While these morphological changes in the rtEa4-
peptide treated cells were further enhanced with time, no such morphological changes were 
observed in untreated cells or cells treated with control protein even after 48 h of culture. To 
confirm that rtEa4-peptide treated cancer cells exhibited apoptosis, MDA-MB-231C cells 
were treated with 3.0 µM of recombinant rtEa4-peptide for 48 h, and the treated cells were 
subjected to TUNEL assay or immuno-cytochemical staining with a mono-specific antibody 
against activated caspase 3. As shown in Figure 2, after incubation for 48 h in a serum free 
medium containing 3.0 µM of recombinant rtEa4-peptide, most of the cells showed positive 
in TUNEL assay (Fig 2A) as well as in immuno-cytochemical staining for activated caspase 3 
(Fig 2B). Furthermore, apoptosis was also observed in ovarian cancer cells, SKOV 3A, 
treated with 1.5 µM of recombinant rtEa4-peptide (Fig 3). These results confirmed that 
rtEa4-peptide induced apoptosis in human breast cancer cells and ovarian cancer cells. 
 
 
Fig. 1. Induction of apoptosis in ovarian cancer cells (A, SKOV-3A) and breast cancer cells 
(B, MDA-MB-231C) by recombinant rtEa4-peptide.  Cancer cells in serum free medium were 
treated with or without rtEa4-peptide for 2 h, and observed under an inverted phase 
contrast microscope (Olympus IX50).  a, control protein; b, 1.4 µM rtEa4-peptide ; c, 2.8  µM 
rtEa4-peptide.  Arrows indicate apoptotic cells.  
Generally speaking, apoptosis can be stimulated via extrinsic and intrinsic pathways. Does 
rtEa4-peptide or hEb-peptide induce apoptosis in cancer cells via both extrinsic and intrinsic 
pathways? It has been reported by many investigators that if apoptosis is induced via 
extrinsic pathway, up-regulation of expression of TRAIL-RI, FADD and pro-Casp-8 genes 
will be observed. On the other hand, if apoptosis is induced via intrinsic pathway, down-
regulation of expression of Bcl-2, Bcl-XL and Mcl-1 genes and up-regulation of expression of  
100 μm 
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Fig. 2. Apoptotic cells identified by TUNEL assay (A) and immunostaining with mono-
specific antibody to activated capase-3 (B).  MDA-MB-231C cells in serum free medium were 
treated with (3.0µM) rtEa4-peptide or control protein for 48 h.  One sample was treated with 
H202 for 16 h to induce apoptosis as a positive control.  TUNEL assay was carried out 
following the protocol supplied by the manufacturer.   Monospecific polyclonal rabbit anti-
activated caspase 3 immunoglobulin was labeled with Rodamine Red and used to stain 
recombinant rtEa4 peptide treated or positive control cells.  The immuno-stained cells were 
observed under an inverted microscope (Olympus IX50) with epifluorescence attachment. 
 
 
Fig. 3. Induction of apoptosis in ovarian cancer cells (SKOV-3A) by rtEa4-peptide.  SKOV-3A 
cells in serum free medium were treated with control protein (A) or 1.5 µM of rtEa4-peptide 
(B) for 3 d, and cells were stained with H33258.  Arrows indicate apoptotic cells.  
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Fig. 4. Effect of recombinant rtEa4- (A) or hEb-peptide (B and C) on levels of Casp-3, Casp-8, 
Casp-9, TRAIL-R1 and Cyt-C mRNAs in MDA-MB-231C cells.  MBA-MD-231C cells in serum 
free medium were treated with various concentrations of recombinant rtEa4- or hEb-peptide 
for 6 h, and total RNA samples were isolated from the treated cells.  The levels of mRNA were 
determined by quantitative relative real-time RT-PCR analysis.  The level of GAPDH mRNA 
was used as an internal control.  Relative Expression Level = 2-(SΔCT-CΔCT), where SΔCT is the 
difference between the CT number of the sample (cancer cells treated with E-peptide) and 
GAPDH, and the CΔCT is the difference between the CT of cancer cells without E-peptide 
treatment and the CT of GAPDH.  Error bars indicate standard deviation (n=3).  
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Fig. 5. A schematic presentation of extrinsic and intrinsic pathways of apoptosis.  Apoptosis 
can be initiated via stimulation at the plasma membrane by death receptor (extrinsic 
pathway) or at mitochondria (intrinsic pathway).  Stimulation of death receptors will result 
in aggregation and recruitment of the adaptor molecule Fas-associated protein with death 
domain (FADD) and pro-caspase 8.  Upon recruitment, pro-caspase 8 is activated to caspase 
8 and initiates apoptosis by direct activating downstream caspases (caspases 3 and 9).  
Intrinsic pathway is initiated by a variety of stress stimuli in which the mitochondrial 
membrane permeability is regulated by balance of opposing action of pro-apoptotic and 
antiapoptotic Bcl family members (Bax, Bak, Bcl2, Bcl-XL and Mcl-1).  Following 
mitochondril permeabilization, mitochondrial proapoptotic proteins such as cytochrome C, 
Samc/Diablo, Omi/HrtA2, AIF and Endo G are released via transmembrane channels 
across the mitochondriasl outer membrane.  This figure was redrawn from information 
provided by Fulda and Debatin (2006). 
Cyt-C gene will be observed (Figure 5) (Fulda and Debatin, 2006; O’Brien and Kirby, 2008 for 
review). Therefore, to address the question whether rtEa4-peptide and hEb-peptide can 
induce apoptosis in cancer cells through both extrinsic and intrinsic pathways, levels of Bcl-
2, Bcl-XL, Casp-3, Casp-8, Casp-9, TRAIL-R1 and Cyt-C mRNAs were measured by 
quantitative relative real-time RT-PCR analysis in MBA-MD-231C cells following treatment 
with recombinant rtEa4- or  hEb-peptide. As shown in Figures 4A, 4B and 4C, upon 
treatment of MDA-MB-231C cells with various doses of recombinant rtEa4- or hEb-peptide, 
a dose-dependent up-regulation on levels of Casp-3, Casp-8, Casp-9, TRAIL-R1 and Cyt-C 
mRNAs and a dose-dependent down-regulation on levels of Bcl-2 and Bcl-XL mRNAs were 
observed. These results suggest that E-peptide may induce apoptosis in breast cancer cells 
via both extrinsic and intrinsic pathways. To further confirm that rtEa4- or hEb-peptide can 
also induce apoptosis in other cancer cells, human ovarian cancer cells (OVCAR-3A, SKOV-
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3B), neuroblastoma cells (SK-N-SH and SK-N-F1) and non-cancerous foreskin cells (CCD-
1112SK) were treated with 2.0 µM of rtEa4-peptide or 0.5 µM hEb-peptide for 6 h and RNA 
samples were extracted for determination of levels of Bcl-2, Bcl-XL, Mcl-1, Casp-3, Casp-8, 
Casp-9, TRAIL-R1, FADD, Cyt-C, p53 and PTEN mRNAs by quantitative relative real-time 
RT-PCR analysis. As shown in Table 2, while the levels of Bcl-2, Bcl-XL and Mcl-1 mRNAs 
in rtEa4-peptide or hEb-peptide treated cancer cells were down-regulated significantly, 
those of Casp-3, Casp-8, Casp-9, TRAIL-R1, FADD, Cyt-C, p53 and PTEN mRNAs were up-
regulated. Results presented in Table 2 not only provide a strong evidence to support the 
hypothesis that rtEa4- or hEb-peptide induces apoptosis in cancer cells via both extrinsic 
and intrinsic pathways, but also confirm the notion that E-peptide can induce apoptosis in 
many cancer cells other than MBA-MD-231C cells.   
 
 
Relative Expression Level 2-[(SΔCT-CΔCT)] and standard deviation (n=3) vhere SΔCT is the difference 
between the CT number of the sample (cancer cells treated with E-peptide) and the house keeping gene 
(GAPDH), and the CΔCT is the difference between the CT of cancer cells without E-peptide treatment 
and the CT of GAPDH 2-[(SΔCT-CΔCT)]>1, up-regulation; 2-[(SΔCT-CΔCT)]<1, down-regulation *CCD-1112SK, 
non-immortalized human fibroblast cells. 
Table 2. Relative Expression Levels of Apoptosis Genes by E-peptide of Pro-IGF I 
It is very interesting to note that treatment of non-cancerous foreskin cells (CCD-1112SK) 
with the same concentration of recombinant rtEa4-peptide or hEb-peptide (result not 
shown) did not result in significant changes in the levels of Bcl-2, Bcl-XL, Mcl-1, Casp-3, 
Casp-8, Casp-9, TRAIL-R1, FADD, Cyt-C, p53 and PTEN mRNAs when compare to non-
treatment control (Table 2). This observation suggests that rtEa4- or hEb-peptide only 
induces apoptosis in cancer cells. The resistance of cancer cells to apoptosis is one of the 
major concerns in cancer therapy. So in searching for effective chemotherapeutic drugs, the 
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effectiveness of the drugs to induce apoptosis in a wide variety of cancer types will be the 
top choice. Although there are numerous chemotherapeutic drugs available on the market 
that have been shown to induce apoptosis in cancer cells, unfortunately these drugs also 
induce apoptosis in non-cancerous cells. In this study we have shown that rtEa4- or hEb-
peptide can induce apoptosis in a variety of human cancer cells but not in non-cancerous 
cells. Therefore, we believe that rtEa4- or hEb-peptide could be developed as an ideal 
therapeutic agent for treating human cancers. 
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